Antipsychotic Drugs: Clinical Pharmacology and Therapeutic Use

Drugs

Volumn 14, Issue 4, 1977, Pages 260-282

  Davis, John M ^a,b   Casper, Regina ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTAPERAZINE; CARFENAZINE; CHLORPROMAZINE; CHLORPROTHIXENE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; PECAZINE; PERPHENAZINE; PROCHLORPERAZINE; PROMAZINE; RESERPINE; THIOPROPAZATE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE;

ADVERSE DRUG REACTION; AKATHISIA; CONVULSION; DOSE RESPONSE; DRUG DETERMINATION; DRUG THERAPY; DYSKINESIA; EDEMA; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HEART ARRHYTHMIA; JAUNDICE; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PHARMACOKINETICS; PHOTOSENSITIZATION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SERUM; SURVEY; TARDIVE DYSKINESIA; THERAPY; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CLINICAL TRIALS; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; HEMODYNAMICS; HUMAN; PSYCHOTIC DISORDERS; RECURRENCE; SCHIZOPHRENIA;

EID: 0017644231     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-197714040-00002     Document Type: Review

References (77)

1. A study of phenothiazines in male and female chronically ill schizophrenics
2. Maintenance therapy of chronic psychotic patients with a weekly oral dose of R 16341
3. Loxapine: A controlled evaluation in chronic schizophrenic patients
4. Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics
5. Discontinuation or reduction of chemotherapy in chronic schizophrenics
6. Combined drug therapy of chronic schizophrenics
7. Loxapine succinate: a controlled double blind study in schizophrenia
8. Molindone in chronic schizophrenia
9. Evaluation of loxapine succinate in chronic schizophrenia
10. Loxapine in newly admitted chronic schizophrenic patients
11. Chlorpromazine in chronic schizophrenia: The effect of age and hospitalisation in behavioral dose-response relationships
12. Phenothiazine treatment in acute schizophrenia
13. Plasma/blood level monitoring techniques in psychiatry
14. Factors affecting chlorpromazine plasma levels in psychiatric patients
15. Plasma levels of chlorpromazine and some of its relatively nonpolar metabolites in psychiatric patients
16. Chlorpromazine plasma levels and effects
17. Dose equivalence of the antipsychotic drugs
18. Comparative doses and costs of antipsychotic medication
19. Oxilapine vs trifluoperazine
20. Deanol in tardive dyskinesia
21. Drug effects and hypothalamic anterior pituitary function
22. Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage
23. Phenothiazines in the prevention of psychiatric hospitalisation
24. The efficacy and safety of loxapine succinate in the treatment of schizophrenia: a comparative study
25. Comparison of trifluoperazine and molindone in chronic schizophrenic patients
26. Prolonged withdrawal of chlorpromazine in chronic patients
27. Molindone: controlled evaluation in chronic schizophrenic patients
28. Papaverine for tardive dyskinesia
29. Pharmacokinetics of red blood cell phenothiazine and clinical effects
30. Withdrawal of ataractic medication in schizophrenic patients
31. Termination of chlorpromazine with schizophrenic patients
32. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment
33. The comparative effectiveness of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients
34. Persistence of extrapyramidal disorders and psychiatric relapse after with-drawal of long-term phenothiazine therapy
35. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine double blind placebo trial
36. Drugs and sociotherapy in the aftercare of schizophrenic patients
37. Drugs and sociotherapy in the aftercare of schizophrenic patients
38. Perphenazine combined with amitriptyline in newly admitted schizophrenics
39. Comparison of the clinical and electroencephalographical effects of molindone and trifluoperazine in acute schizophrenic patients
40. Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism
41. Trial of maintenance therapy in schizophrenics
42. Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients
43. Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis
44. Schizophrenia— A followup study of results of treatment I
45. Schizophrenia — A followup study of results of treatment II
46. Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic inpatients
47. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients
48. Deanol: A solution for tardive dyskinesia
49. Treatment of acute schizophrenia with loxapine succinate (Loxitane) in a controlled study with chlorpromazine
50. A study of withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia
51. A double-bind comparison of loxitane loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients
52. Short-term improvement in schizophrenia: the contribution of background factors
53. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health. Psychopharmacology Research Branch Collaborative Study Group
54. High dose trifluoperazine therapy in chronic schizophrenia
55. Discontinuation of chemotherapy for chronic schizophrenics: results from two collaborative studies
56. Very high dose vs standard dosage fluphenazine in schizophrenia
57. A comparative study of molindone and trifluoperazine
58. Withdrawal of antipsychotic drugs from chronic patients
59. Deanol in L-Dopa and tardive dyskinesia: A Review
60. Comparison of chlorpromazine and reserpine in maintenance drug therapy
61. Loxapine succinate: A controlled double-blind study in chronic schizophrenia
62. A comparison of thioridazine, trifluoperazine, chlorpromazine and placebo: A double blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients
63. A controlled double blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients
64. A double blind comparison of molindone and trifluoperazine in the treatment of acute schizophrenia
65. Loxapine: A double blind comparison with chlorpromazine in acute schizophrenic patients
66. Cholinergic influences in tardive dyskinesia
67. Maintenance phenothiazine in the aftercare of schizophrenic patients
68. Effectiveness of loxapine suc-cinate in acute schizophrenia: A comparative study with thiothixene
69. Withdrawal of perphenazine in chronic schizophrenia
70. Trifluoperazine: A comparison between regular and high doses